The pharmaceutical industry spent a record $168 million in 2007 on lobbying efforts aimed at members of Congress, according to a report released June 24 by the Center for Public Integrity (http://projects.publicintegrity.org/rx/report.aspx?aid=985).
The center's analysts said one reason spending jumped 32% last year compared with 2006 was because of a busy legislative calendar dominated by issues critical to the drug industry. The 2006 takeover of Congress by Democrats likewise fueled the spending and reprioritized drug industry investments. For the first time since 1998, when records of lobbyists' contributions became available, Democrats received slightly more than half of the money vs only 31% in 2006.
Mitka M. Drug Industry Lobbying. JAMA. 2008;300(6):645. doi:10.1001/jama.300.6.645-a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: